$BCLI
Brainstorm Cell Therapeutics Inc

2020 Q2 Form 10-Q Financial Statement

#000110465920090549 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.710M $1.300M
YoY Change 31.54% -19.25%
% of Gross Profit
Research & Development $5.694M $3.554M
YoY Change 60.21% 140.14%
% of Gross Profit
Depreciation & Amortization $50.00K $33.00K
YoY Change 51.52% 6.45%
% of Gross Profit
Operating Expenses $5.694M $3.554M
YoY Change 60.21% 15.02%
Operating Profit -$7.400M -$4.857M
YoY Change 52.36% 57.34%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $10.00K -$40.00K
YoY Change -125.0%
Pretax Income -$7.390M -$4.900M
YoY Change 50.82% 58.58%
Income Tax
% Of Pretax Income
Net Earnings -$7.394M -$4.900M
YoY Change 50.9% 58.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$252.5K -$225.8K
COMMON SHARES
Basic Shares Outstanding 21.70M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.19M $2.700M
YoY Change 499.63% -84.52%
Cash & Equivalents $12.15M $1.126M
Short-Term Investments $4.040M $1.580M
Other Short-Term Assets $180.0K $920.0K
YoY Change -80.43% -20.69%
Inventory
Prepaid Expenses
Receivables $260.0K $1.920M
Other Receivables $0.00 $0.00
Total Short-Term Assets $16.63M $5.540M
YoY Change 200.14% -71.68%
LONG-TERM ASSETS
Property, Plant & Equipment $918.0K $3.300M
YoY Change -72.18% 450.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.593M $30.00K
YoY Change 8543.33% -96.51%
Total Long-Term Assets $2.593M $3.320M
YoY Change -21.9% 127.4%
TOTAL ASSETS
Total Short-Term Assets $16.63M $5.540M
Total Long-Term Assets $2.593M $3.320M
Total Assets $19.22M $8.860M
YoY Change 116.94% -57.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.604M $8.770M
YoY Change -47.5% 109.81%
Accrued Expenses $2.022M $1.020M
YoY Change 98.24% -30.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.840M $10.54M
YoY Change -16.13% 29.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $560.0K $2.840M
YoY Change -80.28%
Total Long-Term Liabilities $559.0K $2.840M
YoY Change -80.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.840M $10.54M
Total Long-Term Liabilities $559.0K $2.840M
Total Liabilities $9.399M $13.38M
YoY Change -29.75% 64.17%
SHAREHOLDERS EQUITY
Retained Earnings -$132.8M
YoY Change
Common Stock $142.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.822M -$4.516M
YoY Change
Total Liabilities & Shareholders Equity $19.22M $8.860M
YoY Change 116.94% -57.85%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$7.394M -$4.900M
YoY Change 50.9% 58.58%
Depreciation, Depletion And Amortization $50.00K $33.00K
YoY Change 51.52% 6.45%
Cash From Operating Activities -$5.662M -$3.508M
YoY Change 61.4% -6478.18%
INVESTING ACTIVITIES
Capital Expenditures $50.00K $21.00K
YoY Change 138.1% -90.23%
Acquisitions
YoY Change
Other Investing Activities -$2.020M $1.410M
YoY Change -243.26% -111.0%
Cash From Investing Activities -$2.070M $1.391M
YoY Change -248.81% -110.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.414M 5.000K
YoY Change 148180.0% -99.96%
NET CHANGE
Cash From Operating Activities -5.662M -3.508M
Cash From Investing Activities -2.070M 1.391M
Cash From Financing Activities 7.414M 5.000K
Net Change In Cash -318.0K -2.112M
YoY Change -84.94% 114.63%
FREE CASH FLOW
Cash From Operating Activities -$5.662M -$3.508M
Capital Expenditures $50.00K $21.00K
Free Cash Flow -$5.712M -$3.529M
YoY Change 61.86% 2105.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23174228
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29669855
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2022000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1000000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31527937
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12153000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
536000
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
4040000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
33000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1224000
CY2020Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
259000
CY2019Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2359000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
176000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
432000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
16628000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3360000
CY2020Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
26000
CY2019Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
32000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1649000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2182000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
918000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
960000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2593000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3174000
CY2020Q2 us-gaap Assets
Assets
19221000
CY2019Q4 us-gaap Assets
Assets
6534000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4604000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14677000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1263000
CY2020Q2 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
990000
CY2019Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
714000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8840000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17654000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
559000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1103000
CY2020Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
559000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1103000
CY2020Q2 us-gaap Liabilities
Liabilities
9399000
CY2019Q4 us-gaap Liabilities
Liabilities
18757000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29669855
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23174228
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
105042000
CY2020Q2 bcli Receipts On Account Of Shares
ReceiptsOnAccountOfShares
0
CY2019Q4 bcli Receipts On Account Of Shares
ReceiptsOnAccountOfShares
0
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132784000
CY2020Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-6000
CY2019Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
43000
us-gaap Net Income Loss
NetIncomeLoss
-15508000
us-gaap Net Income Loss
NetIncomeLoss
-9927000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7394000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-4900000
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.56
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.47
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
142594000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117276000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9822000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19221000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6534000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11642000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7010000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5694000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3554000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4066000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2775000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1706000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1303000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15708000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9785000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7400000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4857000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-200000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
142000
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.25
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.23
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27452750
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21312335
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29274130
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21703001
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
5016000
CY2019 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
25000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
764000
CY2019 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
2064000
CY2019 bcli Stock Issued During Period Value Exercise And Reissuance Of Warrants
StockIssuedDuringPeriodValueExerciseAndReissuanceOfWarrants
3126000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-23253000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1181000
bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
26383000
CY2019Q2 us-gaap Depreciation
Depreciation
33000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9957000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
us-gaap Net Income Loss
NetIncomeLoss
-15508000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9822000
us-gaap Profit Loss
ProfitLoss
-15508000
us-gaap Profit Loss
ProfitLoss
-9927000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-7394000
CY2019Q2 us-gaap Profit Loss
ProfitLoss
-4900000
us-gaap Depreciation
Depreciation
99000
us-gaap Depreciation
Depreciation
77000
CY2020Q2 us-gaap Depreciation
Depreciation
50000
CY2020Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2019Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1181000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
365000
CY2020Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
791000
CY2019Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
53000
bcli Finance Lease Expense Income
FinanceLeaseExpenseIncome
-50000
bcli Finance Lease Expense Income
FinanceLeaseExpenseIncome
138000
CY2020Q2 bcli Finance Lease Expense Income
FinanceLeaseExpenseIncome
35000
CY2019Q2 bcli Finance Lease Expense Income
FinanceLeaseExpenseIncome
44000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-2362000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-648000
CY2020Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-284000
CY2019Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
801000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-10073000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4217000
CY2020Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
33000
CY2019Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3736000
CY2020Q2 bcli Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
0
CY2019Q2 bcli Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
-511000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1298000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
114000
CY2020Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
539000
CY2019Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1162000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20691000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4343000
CY2020Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5662000
CY2019Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3508000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
CY2020Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
CY2019Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
4007000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-4547000
CY2020Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
2020000
CY2019Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-1412000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4064000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4522000
CY2020Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2070000
CY2019Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1391000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2020Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2019Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
bcli Proceeds From At Market
ProceedsFromAtMarket
26383000
CY2020Q2 bcli Proceeds From At Market
ProceedsFromAtMarket
7411000
CY2019Q2 bcli Proceeds From At Market
ProceedsFromAtMarket
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9957000
CY2020Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2019Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36372000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000
CY2020Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7414000
CY2019Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11617000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
184000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-318000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2112000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
536000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
942000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12471000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3238000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12153000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1126000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12153000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1126000
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 58.3pt;"><b style="font-size:10pt;font-weight:bold;">D.     </b><b style="font-weight:bold;"> </b><b style="font-size:10pt;font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P6M
CY2019 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P6M
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
276000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1649000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1783000
us-gaap Operating Lease Payments
OperatingLeasePayments
653000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1649000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M23D
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
653000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1243000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1896000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
113000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1783000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000.0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000
CY2020Q1 us-gaap Share Price
SharePrice
8.00
CY2020Q1 bcli Warrant Term
WarrantTerm
P3Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
101000000
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1393410
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0173
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.63
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1181000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
365000
us-gaap Share Based Compensation
ShareBasedCompensation
1181000
us-gaap Share Based Compensation
ShareBasedCompensation
390000

Files In Submission

Name View Source Status
0001104659-20-090549-index-headers.html Edgar Link pending
0001104659-20-090549-index.html Edgar Link pending
0001104659-20-090549.txt Edgar Link pending
0001104659-20-090549-xbrl.zip Edgar Link pending
bcli-20200630.xsd Edgar Link pending
bcli-20200630x10q.htm Edgar Link pending
bcli-20200630x10q_htm.xml Edgar Link completed
bcli-20200630xex10d1.htm Edgar Link pending
bcli-20200630xex10d2.htm Edgar Link pending
bcli-20200630xex31d1.htm Edgar Link pending
bcli-20200630xex31d2.htm Edgar Link pending
bcli-20200630xex32d1.htm Edgar Link pending
bcli-20200630xex32d2.htm Edgar Link pending
bcli-20200630_cal.xml Edgar Link unprocessable
bcli-20200630_def.xml Edgar Link unprocessable
bcli-20200630_lab.xml Edgar Link unprocessable
bcli-20200630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending